Albion Financial Group UT Purchases 250 Shares of Danaher Co. (NYSE:DHR)

Albion Financial Group UT raised its position in shares of Danaher Co. (NYSE:DHR) by 833.3% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 280 shares of the conglomerate’s stock after purchasing an additional 250 shares during the period. Albion Financial Group UT’s holdings in Danaher were worth $78,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Boston Common Asset Management LLC raised its position in Danaher by 1.6% during the 3rd quarter. Boston Common Asset Management LLC now owns 101,849 shares of the conglomerate’s stock valued at $28,316,000 after purchasing an additional 1,626 shares in the last quarter. Capital Insight Partners LLC raised its position in shares of Danaher by 3.6% in the 3rd quarter. Capital Insight Partners LLC now owns 3,201 shares of the conglomerate’s stock worth $890,000 after acquiring an additional 112 shares in the last quarter. SS&H Financial Advisors Inc. bought a new position in shares of Danaher in the 3rd quarter worth $255,000. Steigerwald Gordon & Koch Inc. raised its position in shares of Danaher by 0.3% in the 3rd quarter. Steigerwald Gordon & Koch Inc. now owns 16,652 shares of the conglomerate’s stock worth $4,630,000 after acquiring an additional 48 shares in the last quarter. Finally, UMB Bank n.a. raised its position in shares of Danaher by 19.2% in the 3rd quarter. UMB Bank n.a. now owns 113,095 shares of the conglomerate’s stock worth $31,443,000 after acquiring an additional 18,254 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently commented on DHR. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Evercore ISI boosted their price target on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. TD Cowen boosted their price target on Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, July 24th. Stephens started coverage on Danaher in a research note on Tuesday, October 1st. They set an “overweight” rating and a $315.00 target price on the stock. Finally, Stifel Nicolaus boosted their target price on Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and a consensus price target of $282.12.

Insider Activity

In other news, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now owns 97,983 shares of the company’s stock, valued at $27,435,240. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at $27,435,240. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 39,659 shares of company stock valued at $11,042,433 in the last quarter. 11.10% of the stock is currently owned by company insiders.

Danaher Stock Up 1.5 %

Danaher stock opened at $270.34 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The business’s 50-day simple moving average is $270.31 and its two-hundred day simple moving average is $259.13. The company has a market cap of $195.24 billion, a PE ratio of 48.02, a PEG ratio of 4.49 and a beta of 0.83. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.15. The business had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.05 EPS. Equities analysts anticipate that Danaher Co. will post 7.59 EPS for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be issued a $0.27 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.40%. Danaher’s dividend payout ratio (DPR) is presently 19.18%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.